Vicore Pharma Holding AB (publ) (VICO)
Free
No email, no account, no signup.
Pulling latest news for Vicore Pharma Holding AB (publ)…
Bull
Bear
Professional stock analysis at introductory pricing. 7-day money-back guarantee — no lock-in.
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99 $1.25.
Get the deep 4-model report – Signal
HOLD
Sentiment
7/10
Risk
7/10
Get full analysis with Bull/Bear case, catalysts, and risk analysis
Buy express analysis –
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Sentiment has improved modestly on ASPIRE being fully recruited and the board’s commercial strengthening, but the market remains centered on binary risk into the 2027 topline readout and ongoing burn rate.
Exchange
Nasdaq Stockholm
Type
Biotech
Sector
Drug development in fibrotic lung diseases
Market Cap
$257M
Market sentiment
Sentiment has improved modestly on ASPIRE being fully recruited and the board’s commercial strengthening, but the market remains centered on binary risk into the 2027 topline readout and ongoing burn rate.
Why HOLD ?
Maintain HOLD: ASPIRE full recruitment reduces near-term execution risk and funding remains solid, but the key value driver is still binary (ASPIRE topline) with a long time to readout.
- Keep the current position; consider adding only on clear data-driven signals (e.g., strong ATS/biomarker support) or on a larger dip without fundamental deterioration. Alternatively, scale exposure closer to the 2027 readout if risk budget allows.
Recent News
- Since the last analysis: (1) On 2026-05-22 Vicore filed a registration statement (Form 20-F) with the SEC and proceeded with a planned US secondary listing/dual listing with no new share issuance. (2) On 2026-06-02 the company announced a webcast (June 8) to discuss buloxibutid and the IPF landscape including the Phase 2b ASPIRE status. (3) On 2026-06-09 an F-6/A was filed for an ADS program (1 ADS = 10 shares; up to 500M ADS registered; stated max amount ~USD 25m). The share price declined notably in late May/early June with unusually high volume on some days.
Bull case
- **Strong cash balance** after the directed raise reduces near-term funding pressure.
- **ASPIRE enrollment** nearing completion can support positive news flow.
Unlock to read more →
Bear case
- **High burn rate** can weigh on sentiment without new data.
Unlock to read more →
Catalysts
15 Nov 2026 — AGM: issuance authority/incentives
Dilution Risk
Assessment: Medium
Order analysis – $4.99 $1.25
Save hours of research. $4.99 $1.25.
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Want to read the full analysis?
Order a fresh analysis of Vicore Pharma Holding AB (publ) – ready in your inbox in 5–15 minutes.
- Signal + risk + sentiment
- Bull/Bear case + triggers
- Catalysts with dates
- Saved as a webpage in your account
- Ready in 5–15 min (email when ready)
Full analysis at introductory pricing — 7-day money-back guarantee.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Fact-based analysis
Updated weekly
No commitment period
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.